อ้างอิง ของ เอ็มอาร์เอ็นเอที่ดัดแปลงนิวคลีโอไซด์

  1. ↑ Chien, KR; Zangi, L; Lui, KO (October 2014). "Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine". Cold Spring Harbor Perspectives in Medicine. 5 (1): a014035. doi:10.1101/cshperspect.a014035. PMC 4292072. PMID 25301935.
  2. ↑ Alberts, B; Johnson, A; Lewis, J; Raff, M; Roberts, K; Walter, P (2002). From DNA to RNA (4 ed.). Garland Science.
  3. ↑ Pardi, N; Weissman, D (2017). "Nucleoside Modified mRNA Vaccines for Infectious Diseases". RNA Vaccines. Methods in Molecular Biology. 1499. Clifton, N.J. pp. 109–121. doi:10.1007/978-1-4939-6481-9_6. ISBN 978-1-4939-6479-6. PMID 27987145.
  4. ↑ Lodish, H; Berk, A; Zipursky, SL; Matsudaira, P; Baltimore, D; Darnell, J (2000). The Three Roles of RNA in Protein Synthesis (4th ed.). New York: W. H. Freeman. pp. Sec 4.4.
  5. 1 2 3 Schlake, T; Thess, A; Fotin-Mleczek, M; Kallen, KJ (November 2012). "Developing mRNA-vaccine technologies". RNA Biology. 9 (11): 1319–30. doi:10.4161/rna.22269. PMC 3597572. PMID 23064118.
  6. ↑ Dalpke, A; Helm, M (June 2012). "RNA mediated Toll-like receptor stimulation in health and disease". RNA Biology. 9 (6): 828–42. doi:10.4161/rna.20206. PMC 3495747. PMID 22617878.
  7. ↑ Karikó, K; Buckstein, M; Ni, H; Weissman, D (August 2005). "Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA". Immunity. 23 (2): 165–75. doi:10.1016/j.immuni.2005.06.008. PMID 16111635.
  8. 1 2 Svitkin, YV; Cheng, YM; Chakraborty, T; Presnyak, V; John, M; Sonenberg, N (June 2017). "N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density". Nucleic Acids Research. 45 (10): 6023–6036. doi:10.1093/nar/gkx135. PMC 5449617. PMID 28334758.
  9. ↑ Hoernes, TP; Clementi, N; Faserl, K; Glasner, H; Breuker, K; Lindner, H; และคณะ (January 2016). "Nucleotide modifications within bacterial messenger RNAs regulate their translation and are able to rewire the genetic code". Nucleic Acids Research. 44 (2): 852–62. doi:10.1093/nar/gkv1182. PMC 4737146. PMID 26578598.
  10. ↑ von Niessen AG, Orlandini; Poleganov, MA; Rechner, C; Plaschke, A; Kranz, LM; Fesser, S; และคณะ (April 2019). "Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening". Molecular Therapy. 27 (4): 824–836. doi:10.1016/j.ymthe.2018.12.011. PMC 6453560. PMID 30638957.
  11. "Cell Membranes". Kimball's Biology Pages.
  12. ↑ Zhao, L; Seth, A; Wibowo, N; Zhao, CX; Mitter, N; Yu, C; Middelberg, AP (January 2014). "Nanoparticle vaccines". Vaccine. 32 (3): 327–37. doi:10.1016/j.vaccine.2013.11.069. PMID 24295808.
  13. ↑ Carlsson, L; Clarke, JC; Yen, C; Gregoire, F; Albery, T; Billger, M; และคณะ (June 2018). "VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine". Molecular Therapy. Methods & Clinical Development. 9: 330–346. doi:10.1016/j.omtm.2018.04.003. PMC 6054703. PMID 30038937.
  14. ↑ "Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19". www.businesswire.com. 2020-12-12.
  15. ↑ Polack, FP; Thomas, SJ; Kitchin, N; Absalon, J; Gurtman, A; Lockhart, S; และคณะ (December 2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". The New England Journal of Medicine. doi:10.1056/NEJMoa2034577. PMC 7745181 Check |pmc= value (help). PMID 33301246 Check |pmid= value (help). S2CID 228087117.
  16. ↑ Hohmann-Jeddi, C (2020-11-10). "Hoffnungsträger BNT162b2: Wie funktionieren mRNA-Impfstoffe?". Pharmazeutische Zeitung (ภาษาเยอรมัน). สืบค้นเมื่อ 2020-11-28.
  17. ↑ Abbasi, J (September 2020). "COVID-19 and mRNA Vaccines-First Large Test for a New Approach". JAMA. 324 (12): 1125–1127. doi:10.1001/jama.2020.16866. PMID 32880613. S2CID 221476409.
  18. ↑ Vogel, A; Kanevsky, I; Che, Y; Swanson, K; Muik, A; Vormehr, M; และคณะ (2020-09-08). "A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates" (PDF). bioRxiv. doi:10.1101/2020.09.08.280818. S2CID 221589144. Explicit use of et al. in: |last7= (help)
  19. ↑ "Conditions of Authorisation for Pfizer/BioNTech COVID-19 Vaccine" (Decision). Medicines & Healthcare Products Regulatory Agency. 2020-12-08.
  20. ↑ Office of the Commissioner (2020-12-14). "Pfizer-BioNTech COVID-19 Vaccine". www.fda.gov (Decision). US FDA.
  21. ↑ Krammer, F (October 2020). "SARS-CoV-2 vaccines in development". Nature. 586 (7830): 516–527. doi:10.1038/s41586-020-2798-3. PMID 32967006. S2CID 221887746.
  22. ↑ "COVID-19: Über CureVacs Entwicklung eines mRNA-basierten Impfstoffs". curevac.com (ภาษาเยอรมัน). CureVac. 2020-11-28. สืบค้นเมื่อ 2020-11-28.
  23. 1 2 "COVID-19". CureVac. สืบค้นเมื่อ 2020-12-21.
  24. ↑ "Moderna's Pipeline". Moderna. สืบค้นเมื่อ 2020-11-28.
  25. ↑ Dolgin, Elie (2020-11-25). "COVID-19 vaccines poised for launch, but impact on pandemic unclear". Nature Biotechnology: d41587-020-00022-y. doi:10.1038/d41587-020-00022-y. PMID 33239758 Check |pmid= value (help). S2CID 227176634.
  26. ↑ Kaur, K; Zangi, L (December 2020). "Modified mRNA as a Therapeutic Tool for the Heart". Cardiovascular Drugs and Therapy. 34 (6): 871–880. doi:10.1007/s10557-020-07051-4. PMC 7441140. PMID 32822006.
  27. ↑ Zangi, L; Lui, KO; von Gise, A; Ma, Q; Ebina, W; Ptaszek, LM; และคณะ (October 2013). "Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction". Nature Biotechnology. 31 (10): 898–907. doi:10.1038/nbt.2682. PMC 4058317. PMID 24013197.
  28. ↑ McNamara, Megan A.; Nair, Smita K.; Holl, Eda K. (2015). "RNA-Based Vaccines in Cancer Immunotherapy". Journal of Immunology Research. 2015: 794528. doi:10.1155/2015/794528. PMC 4668311. PMID 26665011.
  29. ↑ Verbeke, R; Lentacker, I; Wayteck, L; Breckpot, K; Van Bockstal, M; Descamps, B; Vanhove, C; De Smedt, SC; Dewitte, H (2017-11-28). "Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA". Journal of Controlled Release : Official Journal of the Controlled Release Society. 266: 287–300. doi:10.1016/j.jconrel.2017.09.041. PMID 28987878. S2CID 20794075.

ใกล้เคียง

เอ็มอาร์เอ็นเอที่ดัดแปลงนิวคลีโอไซด์ เอ็มอร พานุสิทธิ์ เอ็มอาร์ทีวี-4 เอ็มอาร์เอ็นเอ เอ็มอาร์ที เอ็มอาร์ไอ เอ็มอาร์ที (แก้ความกำกวม) เอ็มอีเอ เอ็มอีโออาเรนา เอ็ม อรรถพล

แหล่งที่มา

WikiPedia: เอ็มอาร์เอ็นเอที่ดัดแปลงนิวคลีโอไซด์ http://www.nature.com/articles/s41586-020-2798-3 http://users.rcn.com/jkimball.ma.ultranet/BiologyP... http://link.springer.com/10.1007/s10557-020-07051-... //pubmed.ncbi.nlm.nih.gov/16111635 //pubmed.ncbi.nlm.nih.gov/22617878 //pubmed.ncbi.nlm.nih.gov/23064118 //pubmed.ncbi.nlm.nih.gov/24013197 //pubmed.ncbi.nlm.nih.gov/24295808 //pubmed.ncbi.nlm.nih.gov/25301935 //pubmed.ncbi.nlm.nih.gov/26578598